<DOC>
	<DOCNO>NCT01297179</DOCNO>
	<brief_summary>The objective study determine effect multiple dos mirabegron pharmacokinetics oral contraceptive .</brief_summary>
	<brief_title>A Study Evaluate Possible Effects Taking Mirabegron While Taking Contraceptive Pill</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Subjects 35 year inclusive reevaluate risk use COC Body Mass Index 18.5 30.0 kg/m2 , inclusive On oral contraceptive 30ʯg ethinyl estradiol ( EE ) plus either 125ʯg 150ʯg levonorgestrel ( LNG ) least three month prior date randomization well tolerate During study subject willing use 1 3 follow contraceptive method : diaphragm spermicide , intrauterine device partner use condom combination spermicidal cream Subjects exclude participation follow apply : Known suspected hypersensitivity YM178 component formulation use Pregnant breast feeding within 6 month screen assessment Any liver function test ( i.e . ALT , AST Alkaline phosphatase ) upper limit normal Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug ( exclude nonactive Hayfever ) Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic judge medical investigator Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test Abnormal pulse and/or blood pressure measurement prestudy visit follow : Pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 140 mmHg ; mean diastolic blood pressure &gt; 90 mmHg ( blood pressure measurement take triplicate subject rest supine position 5 min ; pulse measure automatically ) A marked baseline prolongation QT/QTc interval repeat measurement &gt; 450 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) Use prescribed OTC ( overthecounter ) drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit Any use drug abuse within 3 month prior admission Clinical Unit History drink 14 unit alcohol per week ( 1 unit = 270 cc beer 40 cc spirit 1 glass wine ) within 3 month prior admission Clinical Unit Positive test drug abuse positive alcohol test day admission clinical unit History smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission Clinical Unit Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study Donation blood blood product within 3 month prior admission Clinical Unit Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 Subjects , opinion investigator , likely complete trial reason Unwillingness use additional barrier contraceptive method course study one month end study visit Any clinical condition , , opinion investigator would allow safe completion study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Oral contraceptive</keyword>
	<keyword>Drug interaction</keyword>
	<keyword>Pharmacokinetics mirabegron</keyword>
</DOC>